NO20090057L - Regulatoriske nukleinsyre elementer - Google Patents
Regulatoriske nukleinsyre elementerInfo
- Publication number
- NO20090057L NO20090057L NO20090057A NO20090057A NO20090057L NO 20090057 L NO20090057 L NO 20090057L NO 20090057 A NO20090057 A NO 20090057A NO 20090057 A NO20090057 A NO 20090057A NO 20090057 L NO20090057 L NO 20090057L
- Authority
- NO
- Norway
- Prior art keywords
- elements
- expression
- sequence
- gene
- well
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101000849522 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S13 Proteins 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 230000002759 chromosomal effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117862 | 2006-07-26 | ||
| PCT/EP2007/055954 WO2008012142A1 (de) | 2006-07-26 | 2007-06-15 | Regulatorische nukleinsäureelemente |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090057L true NO20090057L (no) | 2009-02-16 |
Family
ID=37441548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090057A NO20090057L (no) | 2006-07-26 | 2009-01-06 | Regulatoriske nukleinsyre elementer |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20080124760A1 (ru) |
| EP (1) | EP2049671B1 (ru) |
| JP (1) | JP5270544B2 (ru) |
| KR (1) | KR101485853B1 (ru) |
| CN (1) | CN101517085B (ru) |
| AR (1) | AR061472A1 (ru) |
| AU (1) | AU2007278368B2 (ru) |
| BR (1) | BRPI0714594A2 (ru) |
| CA (1) | CA2658595C (ru) |
| CY (1) | CY1113711T1 (ru) |
| DK (1) | DK2049671T3 (ru) |
| EA (1) | EA016880B1 (ru) |
| ES (1) | ES2401654T3 (ru) |
| IL (1) | IL196676A0 (ru) |
| MX (1) | MX2009000781A (ru) |
| NO (1) | NO20090057L (ru) |
| NZ (1) | NZ575115A (ru) |
| PL (1) | PL2049671T3 (ru) |
| PT (1) | PT2049671E (ru) |
| SI (1) | SI2049671T1 (ru) |
| TW (1) | TW200815591A (ru) |
| WO (1) | WO2008012142A1 (ru) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| CN103620034B (zh) | 2011-04-13 | 2016-12-14 | 加拿大国家研究委员会 | 具有来自IFNα2的SAR元件的表达系统 |
| EP3378535B1 (en) | 2011-10-28 | 2023-01-04 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| KR102285184B1 (ko) * | 2011-12-22 | 2021-08-03 | 에프. 호프만-라 로슈 아게 | 발현 벡터 구성원 조합, 신규한 제조 세포 생성 방법 및 폴리펩티드의 재조합적 제조를 위한 그의 용도 |
| KR102086061B1 (ko) | 2012-01-27 | 2020-03-11 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
| US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
| EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| US10059761B2 (en) | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| EP3116911B8 (en) | 2014-03-12 | 2019-10-23 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| US20170158755A1 (en) | 2014-03-12 | 2017-06-08 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
| WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| NZ735054A (en) * | 2015-02-02 | 2022-09-30 | Meiragtx Uk Ii Ltd | Regulation of gene expression by aptamer-mediated modulation of alternative splicing |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3350226A2 (en) | 2015-09-16 | 2018-07-25 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| EP3478715A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CA3076313A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| BR112020010483A2 (pt) | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| JP7623699B2 (ja) | 2018-11-08 | 2025-01-29 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| PL3817773T3 (pl) | 2018-11-26 | 2024-10-28 | Forty Seven, Inc. | Humanizowane przeciwciała przeciwko c-kit |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US20230235048A1 (en) | 2020-06-24 | 2023-07-27 | Andriani IOANNOU | Antibodies recognizing sortilin |
| WO2022226005A1 (en) * | 2021-04-21 | 2022-10-27 | Janssen Biotech, Inc. | Materials and methods for improved phosphotransferases |
| AR133830A1 (es) | 2023-09-15 | 2025-11-05 | Prothena Platform Tech Limited | Métodos, composiciones y kits que incluyen agentes de penetración celular |
| WO2025059486A1 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Anti-tdp-43 antibodies and uses thereof |
| TW202530246A (zh) | 2023-09-15 | 2025-08-01 | 愛爾蘭商歐賽爾普羅希那有限公司 | 細胞穿透劑及其用途 |
| WO2025059515A2 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Cell penetrating agents and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
| DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp., Seattle, Wash. | Bifunktionelle wählbare fusionsgene |
| US5786166A (en) | 1991-10-25 | 1998-07-28 | University Of Tennessee Research Corporation | Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| CA2163427A1 (en) | 1993-05-21 | 1994-12-08 | Stephen D. Lupton | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| DE19539493A1 (de) * | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| KR19990077015A (ko) * | 1996-01-11 | 1999-10-25 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 진핵 세포 발현 시스템을 위한 발현 증강 서열 요소 (ease) |
| ATE502116T1 (de) | 1998-12-11 | 2011-04-15 | Clontech Lab Inc | Fluoreszierende proteine aus nicht- biolumineszenten arten der klasse anthozoa, gene die diese proteine kodieren und deren verwendungen |
| WO2000034326A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
| WO2000034325A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
| AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
| ES2257303T3 (es) | 1999-07-12 | 2006-08-01 | Genentech, Inc. | Vectores de expresion y procedimientos. |
| EP2308974A3 (en) | 1999-10-14 | 2011-08-10 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
| CA2443275C (en) | 2001-04-05 | 2013-02-05 | Ml Laboratories Plc | Improved gene expression |
| ATE466943T1 (de) | 2001-07-04 | 2010-05-15 | Chromagenics Bv | Dns-sequenzen mit anti-repressor aktivität |
| ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
| US7344886B2 (en) * | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
-
2007
- 2007-06-13 US US11/762,240 patent/US20080124760A1/en not_active Abandoned
- 2007-06-14 TW TW096121483A patent/TW200815591A/zh unknown
- 2007-06-15 CN CN2007800359296A patent/CN101517085B/zh active Active
- 2007-06-15 MX MX2009000781A patent/MX2009000781A/es active IP Right Grant
- 2007-06-15 WO PCT/EP2007/055954 patent/WO2008012142A1/de not_active Ceased
- 2007-06-15 PL PL07730192T patent/PL2049671T3/pl unknown
- 2007-06-15 ES ES07730192T patent/ES2401654T3/es active Active
- 2007-06-15 NZ NZ575115A patent/NZ575115A/en not_active IP Right Cessation
- 2007-06-15 AR ARP070102632A patent/AR061472A1/es active IP Right Grant
- 2007-06-15 JP JP2009521178A patent/JP5270544B2/ja active Active
- 2007-06-15 EP EP07730192A patent/EP2049671B1/de active Active
- 2007-06-15 SI SI200731174T patent/SI2049671T1/sl unknown
- 2007-06-15 CA CA2658595A patent/CA2658595C/en active Active
- 2007-06-15 EA EA200900212A patent/EA016880B1/ru not_active IP Right Cessation
- 2007-06-15 PT PT77301927T patent/PT2049671E/pt unknown
- 2007-06-15 AU AU2007278368A patent/AU2007278368B2/en active Active
- 2007-06-15 DK DK07730192.7T patent/DK2049671T3/da active
- 2007-06-15 BR BRPI0714594-2A patent/BRPI0714594A2/pt not_active IP Right Cessation
- 2007-06-15 KR KR1020097004079A patent/KR101485853B1/ko active Active
-
2009
- 2009-01-06 NO NO20090057A patent/NO20090057L/no not_active Application Discontinuation
- 2009-01-22 IL IL196676A patent/IL196676A0/en unknown
-
2010
- 2010-07-23 US US12/842,468 patent/US9045776B2/en active Active
-
2013
- 2013-02-21 CY CY20131100160T patent/CY1113711T1/el unknown
-
2015
- 2015-04-29 US US14/699,182 patent/US9708626B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2658595C (en) | 2016-05-31 |
| ES2401654T3 (es) | 2013-04-23 |
| AR061472A1 (es) | 2008-08-27 |
| EA200900212A1 (ru) | 2009-10-30 |
| SI2049671T1 (sl) | 2013-04-30 |
| US20100311121A1 (en) | 2010-12-09 |
| JP2009544293A (ja) | 2009-12-17 |
| CY1113711T1 (el) | 2016-06-22 |
| CN101517085B (zh) | 2013-08-07 |
| DK2049671T3 (da) | 2013-04-08 |
| KR101485853B1 (ko) | 2015-01-23 |
| NZ575115A (en) | 2011-10-28 |
| JP5270544B2 (ja) | 2013-08-21 |
| PT2049671E (pt) | 2013-01-24 |
| US20080124760A1 (en) | 2008-05-29 |
| BRPI0714594A2 (pt) | 2013-02-19 |
| US9708626B2 (en) | 2017-07-18 |
| US9045776B2 (en) | 2015-06-02 |
| AU2007278368A1 (en) | 2008-01-31 |
| EA016880B1 (ru) | 2012-08-30 |
| KR20090046887A (ko) | 2009-05-11 |
| EP2049671B1 (de) | 2012-12-19 |
| CN101517085A (zh) | 2009-08-26 |
| EP2049671A1 (de) | 2009-04-22 |
| WO2008012142A1 (de) | 2008-01-31 |
| TW200815591A (en) | 2008-04-01 |
| IL196676A0 (en) | 2011-08-01 |
| US20150337333A1 (en) | 2015-11-26 |
| PL2049671T3 (pl) | 2013-05-31 |
| MX2009000781A (es) | 2009-01-29 |
| CA2658595A1 (en) | 2008-01-31 |
| AU2007278368B2 (en) | 2013-12-19 |
| HK1134107A1 (en) | 2010-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090057L (no) | Regulatoriske nukleinsyre elementer | |
| Perez et al. | Influenza A virus-generated small RNAs regulate the switch from transcription to replication | |
| Smith et al. | Inhibition of heat-shock protein 90 reduces Ebola virus replication | |
| Bhattacharyya et al. | Regulatory role of long non coding RNAs (lncRNAs) in neurological disorders: From novel biomarkers to promising therapeutic strategies | |
| García-Dorival et al. | Elucidation of the cellular interactome of Ebola virus nucleoprotein and identification of therapeutic targets | |
| Wang et al. | Polymorphisms in cis‐elements confer SAUR26 gene expression difference for thermo‐response natural variation in Arabidopsis | |
| MX2009003090A (es) | Genes novedosos relacionados con ciclasa de glutaminilo. | |
| WO2007002008A3 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells | |
| Geerts-Dimitriadou et al. | Analysis of the Tomato spotted wilt virus ambisense S RNA-encoded hairpin structure in translation | |
| AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
| ATE440950T1 (de) | Konstrukte und verfahren zur regulation der genexpression | |
| ATE473637T1 (de) | Verwendung der crispr assoziierten gene (cas) | |
| Gultyaev et al. | Influenza virus RNA structure: unique and common features | |
| PE20120115A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
| Widjaja et al. | Competition between influenza A virus genome segments | |
| Kalyani et al. | Post-transcriptional regulation of renalase gene by miR-29 and miR-146 MicroRNAs: implications for cardiometabolic disorders | |
| Liu et al. | Enhanced photosynthetic activity in pak choi hybrids is associated with increased grana thylakoids in chloroplasts | |
| Balestrazzi et al. | Genotoxic stress, DNA repair, and crop productivity | |
| AR065533A1 (es) | Metodos de transcripcion, constructos de adn de repeticion en tandem, productores de proteinas que atacan geminivirus patogenos de plantas a traves de la interrupcion de los factores de transcripcion esenciales de los agentes patogenos | |
| Ritchie et al. | Identification and characterisation of the genomic segment 7 of the infectious salmon anaemia virus genome | |
| Danker et al. | Developmental information but not promoter activity controls the methylation state of histone H3 lysine 4 on two photosynthetic genes in maize | |
| Duvall et al. | Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen | |
| EP2557171A3 (en) | Cambium/Xylem-preferred promoters and uses thereof | |
| Hao et al. | Molecular evolution of paclitaxel biosynthetic genes TS and DBAT of Taxus species | |
| Liao et al. | The orf virus (ORFV) protein OV20. 0 interacts with the microprocessor complex subunit DGCR8 to regulate miRNA biogenesis and ORFV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |